2Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation, 2000, 10:484-486.
3De Mey C. Inverse PK/PD: estimation and differentiation of bioavailability from effect kinetics-observations with beta-adrenoceptor antagonists. Int J Clin Pharmacol Ther, 1997, 35: 453-457.
4Vanhees L, Aubert A, Fagard R, et al. Influence of beta 1- versus beta 2-adrenoceptor blockade on left ventricular function in humans. J Cardiovasc Pharmacol, 1986, 8: 1086-1091.
5De Mey C, Breithaupt-Grogler K, Schloos J, et al. Reproducibility and consistency of the responses to supine bicycle ergometry; evaluation in conjunction with beta 1-adrenoceptor occupancies. Br J Clin Pharmacol, 1994, 38: 480-483.
6Packer M. Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial. J Card Fail, 2003, 9:429-443.
7Kukin ML, Mannino MM, Freudenberger RS, et al. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol, 2000, 35: 45-50.
8Sandberg A, Abrahamsson B, Svenheden A, et al. Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosing. Pharm Res, 1993, 10:28-34.
9Devereux RB,Alonso DR,Lutas EM,et al.Echocardiographic assessment of left ventricular hypertrophy:Comparison to necropsy findings[J].Am J Cardiol,1986,57(6):450-458.
10Doughty RN,Whalley GA,Gamble G,et al.Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease(Australia-New Zealand Heart Failure Research Collaborative Group)[J].J Am Coll Cardiol,1997,29(5):1060-1066.
